Imara

Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel

Retrieved on: 
Wednesday, April 19, 2023
Biotechnology, Health, Clinical Trials, Cardiology, Therapy, Senior, General counsel, Georgetown University Law Center, Cardiovascular disease, Colby College, History, Wilmer Cutler Pickering Hale and Dorr, Running, Acquisition, Executive Committee, Vertex Pharmaceuticals, Merck, S-1 Executive Committee, Economics, Pharmaceutical industry, Imara

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Stephen Migausky as Senior Vice President and General Counsel.

Key Points: 
  • Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Stephen Migausky as Senior Vice President and General Counsel.
  • In this new role, Mr. Migausky will lead Cardurion’s legal organization, including corporate governance and compliance functions.
  • Mr. Migausky brings to Cardurion 15 years of experience guiding biotechnology companies on complex legal issues, corporate strategy, and transactions.
  • “I look forward to working closely with the team to support Cardurion’s growth and evolution as a leading next generation cardiovascular company.”

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

Retrieved on: 
Wednesday, March 15, 2023
Research, Blood, Therapy, Pfizer, Bristol Myers Squibb, Pathology, Partnership, Fibrosis, Mass, Patient, Death, Inflammation, Brigham and Women's Hospital, MBA, Disease, Massachusetts General Hospital, Eli Lilly and Company, Hospital, Sofinnova, HIV disease progression rates, Vaccine, Pharmaceutical industry, Linking and intrusive R, Imara

CAMBRIDGE, Mass., March 15, 2023 /PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, today announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures. Mediar was founded on pioneering fibrosis research from Mass General and Brigham and Women's Hospitals in partnership with Mass General Brigham Ventures with the goal to transform the treatment of fibrotic disease by targeting the myofibroblast, the key cell type driving fibrosis progression. Mediar is led by industry veterans, Chief Executive Officer Rahul Ballal, Ph.D. and Chief Scientific Officer Paul Yaworsky, Ph.D. Dr. Ballal joins Mediar with nearly 20 years of experience in biotech and was most recently CEO of Imara, which recently merged with Enliven Therapeutics. Dr. Yaworsky joined Mediar in 2019 after a successful 21-year career at Pfizer, most recently serving as the COO of inflammation and immunology research. Joining the Mediar board is Nandita Shangari, Ph.D., from Novartis Venture Fund, Maina Bhaman, MBA, from Sofinnova Partners, and Andreas Jurgeit, Ph.D., from Gimv.

Key Points: 
  • Dr. Yaworsky joined Mediar in 2019 after a successful 21-year career at Pfizer, most recently serving as the COO of inflammation and immunology research.
  • Joining the Mediar board is Nandita Shangari, Ph.D., from Novartis Venture Fund, Maina Bhaman, MBA, from Sofinnova Partners, and Andreas Jurgeit, Ph.D., from Gimv.
  • He continued, "We are also progressing promising leads from our two other first-in-class portfolio programs into preclinical in-vivo proof-of-concept studies."
  • Current therapeutic approaches mainly focus on the initiators of fibrosis that modulate the underlying immune responses known to drive disease onset.

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Retrieved on: 
Thursday, February 23, 2023
Therapy, MBA, Wilson Sonsini Goodrich & Rosati, Cooley, Chemistry, Goldman Sachs, Lung cancer, Wilmer Cutler Pickering Hale and Dorr, BCR-ABL, Patient, SVB Securities, Fairmount, Acute leukemia, NSCLC, Jefferies, CML, HER2, Cancer, Pharmaceutical industry, Imara

BOULDER, Colo., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the completion of its previously announced merger. The combined company will operate under the name, Enliven Therapeutics, Inc., and its shares will trade on the Nasdaq Global Select Market on February 24, 2023 under the ticker symbol “ELVN”.

Key Points: 
  • Following the transaction, Enliven is expected to have a cash runway through multiple clinical milestones and into early 2026.
  • Following the reverse stock split and closing of the merger, there are approximately 41.1 million shares of the combined company’s common stock outstanding, with prior Imara stockholders owning approximately 16% and prior Enliven stockholders (including investors in the private placement) holding approximately 84%.
  • Goldman Sachs & Co., LLC, Jefferies and Cowen served as financial advisors and placement agents to Enliven.
  • Wilson Sonsini Goodrich & Rosati served as legal counsel to Enliven, and Cooley as legal counsel to the placement agents.

Imara Announces Stockholder Approval of Merger With Enliven

Retrieved on: 
Wednesday, February 22, 2023
Telephone, Therapy, Cancer, Annual report, Prospectus, Plan, Form, Computershare, Internet, Risk, Patient, CUSIP, Exercise, Sumathi Best Television Current Reporting Award, Agreement, Nature, Sale, Communication, Book, Security (finance), Imara, Mergers and acquisitions

BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara’s stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara’s common stock to the stockholders of Enliven Therapeutics, Inc. (“Enliven”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the “Merger”).

Key Points: 
  • At the special meeting, Imara’s stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara’s common stock to the stockholders of Enliven Therapeutics, Inc. (“Enliven”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the “Merger”).
  • In addition, Imara today announced that it will effect a 1-for-4 reverse stock split of its common stock that will be effective on Thursday, February 23, 2023, prior to the closing of the Merger.
  • The new CUSIP number for the combined company’s common stock following the Merger and the reverse stock split is 29337E 102.
  • Immediately prior to the reverse stock split, Imara will have 400 million authorized shares due to Imara’s receipt of stockholder approval to increase the number of its authorized shares from 200 million to 400 million.

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Retrieved on: 
Wednesday, January 25, 2023
Class Action Lawsuit, Professional Services, Legal, Sale, Therapy, KSF, Imara

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (the “Company”) (NasdaqGS: IMRA) with Enliven Therapeutics, Inc.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Imara Inc. (the “Company”) (NasdaqGS: IMRA) with Enliven Therapeutics, Inc.
  • Under the terms of the proposed transaction, shareholders of Imara are expected to own only approximately 16% of the combined company, subject to certain adjustments.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMRA, AGFS, SAL, HZNP

Retrieved on: 
Sunday, January 22, 2023
Amgen, Horizon Therapeutics, Advertising, NBT, Sale, Fraud, Therapy, Security (finance), Imara

If you are an Imara shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Imara shareholder, click here to learn more about your rights and options .
  • If you are an AgroFresh shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, FORG, KNBE, IMRA

Retrieved on: 
Thursday, December 29, 2022
Vista Equity Partners, ForgeRock, Fraud, Therapy, Thoma Bravo, Provident, NYSE, Advertising, Sale, Security (finance), Imara

If you are a Lakeland shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Lakeland shareholder, click here to learn more about your rights and options .
  • If you are a ForgeRock shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZNP, IMRA

Retrieved on: 
Friday, December 23, 2022
Fraud, Advertising, Sale, Therapy, Amgen, Security (finance), Imara

If you are a Horizon shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Horizon shareholder, click here to learn more about your rights and options .
  • If you are an Imara shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LFG, OFIX, KNBE, IMRA

Retrieved on: 
Friday, November 18, 2022
Advertising, BP, Therapy, Vista Equity Partners, NYSE, Sale, Fraud, Security (finance), Imara

If you are an Archaea shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Archaea shareholder, click here to learn more about your rights and options .
  • If you are an Orthofix shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FORG, IMRA, LFG, MYOV

Retrieved on: 
Sunday, November 13, 2022
BP, Sale, Roivant Sciences, Therapy, NYSE, Advertising, Fraud, Security (finance), Imara

If you are an Imara shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Imara shareholder, click here to learn more about your rights and options .
  • If you are an Archaea shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.